Baidu
map

PLOS ONE:重症监护病房患者谵妄期间的葡萄糖变异性:一项前瞻性队列研究

2018-11-17 海北 MedSci原创

最近,研究人员进行了一项前瞻性队列研究,来探究在重症监护病房(ICU)中,糖尿病和非糖尿病的重症患者谵妄期间葡萄糖变异性与非谵妄期间相比是否有所改变。

最近,研究人员进行了一项前瞻性队列研究,来探究在重症监护病房(ICU)中,糖尿病和非糖尿病的重症患者谵妄期间葡萄糖变异性与非谵妄期间相比是否有所改变。

在这项20111月至20136月期间进行的前瞻性队列研究中,包括了在ICU住院期间患有谵妄和非谵妄的重症患者。研究人员使用各种定义(平均葡萄糖,标准偏差,平均绝对葡萄糖,每日血糖差,以及低血糖和高血糖发生的变化)在每个观察日测量葡萄糖变异性。混合效应模型和具有logit链接功能的广义混合效应模型被用于研究谵妄和葡萄糖变异之间的关联,调整潜在的混杂因素。

除了低血糖的风险之外,使用该估计的各种定义,研究人员发现,谵妄与较高的葡萄糖变异性无关。对于低血糖,研究人员确实发现与糖尿病患者的谵妄有关(OR = 2.78; 95CI1.71-6.32p = 0.005),但非糖尿病患者中没有类似的关联(OR adj.1.16; 95CI 0.58-2.28p = 0.689)。

尽管危重患者的谵妄和低血糖之间存在正相关关系,但谵妄与更明显的葡萄糖变异性无关。该研究结果表明,在ICU谵妄期间,糖尿病患者应更密切地监测血糖水平,以预防低血糖。


原始出处:

van Keulen K et al. Glucose variability during delirium in diabetic and non-diabetic intensive care unit patients- A prospective cohort study. PLOS ONE, 2018; doi: 10.1371/journal.pone.0205637. eCollection 2018.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1937620, encodeId=ba8a193e62010, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Fri Aug 02 07:54:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954314, encodeId=b0b01954314e9, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 27 10:54:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790293, encodeId=68cb1e9029377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Aug 05 10:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006441, encodeId=222c2006441ff, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Fri Nov 23 08:54:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342537, encodeId=55bc134253e5c, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368842, encodeId=d9b8136884244, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551145, encodeId=4cf4155114566, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Mon Nov 19 04:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-19 bioon6

相关资讯

PNAS:慢性社交应激诱导高血糖症以及空间记忆受损

严格的葡萄糖需求使得大脑容易受到这种主要能量供应的干扰,并且慢性压力可能构成这种破坏。然而至今为止,压力相关的认知障碍是否可能由扰乱的葡萄糖调节引起仍不清楚。

使用劣药“葡萄糖注射液”,河南中医药大学第一附属医院受处罚

药品安全无小事,作为一种广泛用于静脉注射的药品,葡萄糖注射液的安全问题影响广泛,8月3日,记者获悉,根据郑州市食品药品监督管理局日前发布的行政处罚案件信息公开表,因为使用劣药“葡萄糖注射液”,河南中医药大学一附院受到处罚。河南中医药大学一附院使用劣药“葡萄糖注射液”遭处罚7月30日,郑州市食品药品监督管理局正式公布(2018年第22期)行政处罚案件信息公开表,5起案件中,河南中医药大学第一附属医

Gut:肠道微生物代谢产物、氨基酸代谢物与胰岛素敏感性和葡萄糖代谢!

由此可见,该研究的结果强调了TMAO、胆碱和左旋肉碱变化在肥胖患者减肥干预过程中改善胰岛素敏感性的重要性。膳食脂肪摄入可改变TMAO与胰岛素敏感性和糖代谢之间的关系。

JACC:天选之人!哈佛科学家在人体内发现神奇的基因突变,与肥胖发生率降低57%、糖尿病发病率降低42%、死亡风险降低34%有关

最近,由美国哈佛大学Scott Solomon博士带领的团队在一个25年的临床队列研究中发现,某个基因上的一些突变能明显减少小肠对葡萄糖的吸收,并长期改善心血管代谢能力。

Diabetic Med:FreeStyle Libre ™葡萄糖传感器数据可以对安全驾驶进行决策吗?

许多国家要求糖尿病患者遵守血糖检测标准,以获得或保留驾驶执照。目前,间质液葡萄糖结果可能不被认可使用。近日,国际杂志 《Diabetic Med》上在线发表一项关于FreeStyle Libre ™葡萄糖传感器数据可以对安全驾驶进行决策的研究。本研究的目的是确定使用快速葡萄糖传感技术测量间质葡萄糖是否可以为增强安全驾驶提供额外信息。 研究人员通过获得FreeStyle Libre Glu

Baidu
map
Baidu
map
Baidu
map